Compare RLX Technology Inc (RLX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs BIO-TECHNE Corp — how do they compare? RLX Technology Inc trades at $1.77 (market cap $2.19B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: BIO-TECHNE Corp is far larger — about 5.2× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (5.59%). Which is the better fit depends on your goals.
| RLX | TECH | |
|---|---|---|
Market Cap | $2.19B | $11.34B |
Sector | Technology | Health |
52-Week High | $2.69 | $72.48 |
52-Week Low | $1.76 | $43.31 |
Enterprise Value | $919.18M | $11.36B |
Dividend Yield | 5.59% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RLX trades at $1.79, down 0.56% on the day, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue growth of 14.8% year-over-year, driven by international expansion, though it missed EPS estimates for the third consecutive quarter. Profitability remains solid with a net income margin of 21.87% and a P/E ratio of 16.1, indicating reasonable valuation.
The outlook is mixed; international growth offers opportunity, but consistent earnings misses and a sole 'Hold' analyst rating suggest caution. Key risks include execution in new markets and regulatory scrutiny. The stock lacks bullish momentum but holds fundamental strength if expansion delivers.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
